HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer ; volume:14 ; number:1 ; day:27 ; month:5 ; year:2024 ; pages:1-14 ; date:12.2024
Scientific reports ; 14, Heft 1 (27.5.2024), 1-14, 12.2024
- Creator
-
Kapil, Ansh
Spitzmüller, Andreas
Brieu, Nicolas
Haneder, Susanne
Shumilov, Anatoliy
Meier, Armin
Cecchi, Fabiola
Barkell, Alice
Harder, Nathalie
Mittermaier, Katrin
Hidalgo-Sastre, Ana
Alleze, Regina
Schick, Markus
Schmidt, Günter
Sade, Hadassah
Tsuchihashi, Zenta
Suto, Fumitaka
Gustavson, Mark
Barrett, J. Carl
Carroll, Danielle
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-61957-9
- URN
-
urn:nbn:de:101:1-2408060902350.387872700786
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kapil, Ansh
- Spitzmüller, Andreas
- Brieu, Nicolas
- Haneder, Susanne
- Shumilov, Anatoliy
- Meier, Armin
- Cecchi, Fabiola
- Barkell, Alice
- Harder, Nathalie
- Mittermaier, Katrin
- Hidalgo-Sastre, Ana
- Alleze, Regina
- Schick, Markus
- Schmidt, Günter
- Sade, Hadassah
- Tsuchihashi, Zenta
- Suto, Fumitaka
- Gustavson, Mark
- Barrett, J. Carl
- Carroll, Danielle
- SpringerLink (Online service)
Other Objects (12)
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Enhertu (Trastuzumab-Deruxtecan) : Therapieerfahrungen bei Patient*innen mit HER2-positivem und HER2-low fortgeschrittenem Mammakarzinom
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Enhertu (Trastuzumab-Deruxtecan) : Therapieerfahrungen bei Patient*innen mit HER2-positivem und HER2-low fortgeschrittenem Mammakarzinom
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Enhertu (Trastuzumab-Deruxtecan) : Therapieerfahrungen bei Patient*innen mit HER2-positivem und HER2-low fortgeschrittenem Mammakarzinom
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE